Bausch Health's brain dysfunction treatment fails late-stage trial
23/01/2026 12:50
Jan 23 (Reuters) - Bausch Health BHC.TO said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Bausch Health Companies
See all newsCanada Stocks: TSX heads for monthly gain as mining stocks rise, oil retreats
Canada's Bausch Health Q1 revenue rises
Canada's Bausch Health beats Q1 adjusted EPS estimates
Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case
Canada Stocks: TSX subdued as healthcare, financials drag; energy gains